Who Owns Veracyte Company?

Veracyte Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns Veracyte?

Unraveling the ownership of a company like Veracyte, a leader in genomic diagnostics, is key to understanding its future. From its inception as Calderome, Inc. in 2006 to its IPO in 2013, Veracyte's journey reflects a fascinating evolution in ownership. Knowing who controls the company can offer critical insights into its strategic direction and potential for growth.

As a publicly traded entity, Veracyte SWOT Analysis reveals a complex ownership structure, primarily influenced by institutional investors. Understanding the dynamics of Veracyte ownership, including its major shareholders and leadership, is crucial for any investor or stakeholder. This analysis will delve into the specifics of who owns Veracyte, providing a comprehensive overview of its ownership and management.

The Veracyte company was co-founded by Bonnie Anderson, who also served as its Chief Executive Officer and Chairman. This information is crucial for understanding the Veracyte ownership structure and the company's early leadership.

While the exact initial equity splits among the founders aren't publicly available, Bonnie Anderson played a key role in guiding the company through its initial public offering (IPO) in 2013 and commercializing its key products. This highlights her significant influence in shaping the company's direction from its inception.

Before its IPO, Veracyte secured $67.9 million in funding from early investors, including General Electric and Domain Associates. These early investments were critical for the company's early growth and development in genomic diagnostics. The vision of transforming cancer care through genomic tests, as articulated by its founders, was a key factor in attracting these foundational investments.

Early Funding and Leadership

Early investors like General Electric and Domain Associates played a crucial role in the initial funding rounds for Veracyte. The company's leadership, particularly Bonnie Anderson, was instrumental in guiding the company through its IPO and commercializing its products. Understanding the early funding is vital for analyzing the company's growth trajectory. The company's focus on genomic diagnostics has been a key factor in attracting investment and shaping its strategic direction. Learn more about the Marketing Strategy of Veracyte.

• Bonnie Anderson's role as CEO and Chairman was pivotal.
• Early funding rounds totaled $67.9 million before the IPO.
• General Electric and Domain Associates were key early investors.
• The company's focus on genomic diagnostics attracted investment.

Veracyte SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The Growth Strategy of Veracyte was significantly impacted by its initial public offering (IPO). On October 30, 2013, the company went public, offering 5,000,000 shares at $13.00 per share. This event raised approximately $58.0 million in net proceeds, shifting the ownership structure to include public shareholders. This marked a pivotal moment in the company's financial journey, paving the way for broader investment and growth.

As of May 2025, the ownership of the Veracyte company is largely influenced by institutional investors. This shift indicates growing confidence in the company's long-term strategy and its ability to grow within the genomic diagnostics sector. The IPO and subsequent institutional investment have shaped the company's financial landscape, supporting its expansion plans and strategic initiatives.

The current Veracyte ownership structure reflects a strong presence of institutional investors. Key players include Vanguard Group Inc. with 10.66% of shares, BlackRock, Inc. holding 8.893%, and FMR LLC with 9.162%. This concentration of ownership by major institutional investors underscores the company's appeal to large investment funds. These entities play a crucial role in shaping the company's strategic direction and financial performance. The increase in mutual fund holdings also indicates a growing interest in Veracyte stock.

Veracyte Ownership Dynamics

Veracyte's ownership structure is primarily influenced by institutional investors, with significant holdings by firms like Vanguard and BlackRock.

• The IPO in 2013 opened the company to public shareholders.
• Institutional investors hold a significant portion of Veracyte stock.
• Individual insiders hold a smaller percentage of shares.
• Mutual funds have increased their holdings.

Veracyte PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The current board of directors of the Veracyte company includes a diverse group of experienced leaders. Members include Eliav Barr, M.D., Muna Bhanji, R.Ph., Karin Eastham, M.B.A., Robert S. Epstein, M.D., M.S., Jens Holstein, Evan Jones, M.B.A., Tom Miller, Ph.D., and Brent Shafer. Marc Stapley, the Chief Executive Officer, also serves on the board. Brent Shafer and Tom Miller, Ph.D., joined the board in September 2024, bringing expertise in the healthcare industry and AI-driven drug discovery.

The board's composition reflects a mix of backgrounds, which likely informs strategic decisions and oversight of the company's operations. The presence of both seasoned executives and individuals with specific industry knowledge suggests a focus on both operational excellence and innovation. The board's role is crucial in guiding the company's direction and ensuring accountability to shareholders. Understanding the Veracyte leadership is key to understanding the company's future.

Veracyte's voting structure is based on one-share-one-vote for common stock. Each share of common stock entitles the holder to one vote for director elections and other stockholder matters. While specific details on dual-class shares or unique voting rights aren't emphasized publicly, the involvement of significant institutional Veracyte investors suggests substantial collective voting power. Directors serve three-year terms, and stockholders cannot cumulate votes in director elections. The ratification of the independent registered public accounting firm is considered routine. Election of directors and advisory votes on executive compensation are non-routine matters, requiring specific instructions from beneficial owners if shares are held in street name. To learn more about the company's strategic direction, you can read about the Growth Strategy of Veracyte.

Voting Power and Board Composition

The board of directors oversees Veracyte's operations and strategic direction.

• Directors are elected for three-year terms.
• Voting is primarily one-share-one-vote.
• Significant institutional investors hold considerable voting power.
• The board includes leaders with diverse expertise.

Veracyte Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, several significant developments have reshaped the ownership profile of the Veracyte company. In May 2021, Bonnie Anderson transitioned from CEO to Executive Chairman, with Marc Stapley taking over as CEO. This leadership change was part of a planned transition. Another key event was the acquisition of Decipher Biosciences, Inc., which was intended to be financed through a public offering in February 2021. This acquisition aimed to boost the commercial expansion of Decipher's tests, especially in the urologic cancer market.

Institutional ownership has increased, a common trend for growing public companies like Veracyte. As of May 2025, approximately 99.5% of shares are held by institutional investors, with insiders owning a much smaller 0.458%. Key institutional shareholders include The Vanguard Group, Inc., FMR LLC, and BlackRock, Inc., with holdings adjusted through March and April 2025. For example, ARK Investment Management LLC reduced its ownership by 35.72% in January 2025 compared to January 2024.

Veracyte's financial performance in early 2025 further highlights its growth. Total revenue for the first quarter of 2025 reached $114.5 million, an 18% increase year-over-year. The company also reported a net income of $7.0 million for the first quarter of 2025, a significant improvement. These positive results can influence investor sentiment and ownership trends. The company is also evaluating the ownership and operations of its French subsidiary, Veracyte SAS, and is considering no longer funding the entity, which could lead to changes in its overall asset structure.

Veracyte Ownership Overview

Institutional investors hold the vast majority of Veracyte stock. Key institutional shareholders include The Vanguard Group, FMR LLC, and BlackRock, Inc. Insiders own a smaller percentage of the company's shares. This ownership structure reflects a trend of institutional interest in the company.

Recent Financial Performance

The company's financial performance in early 2025 shows growth. Revenue for Q1 2025 increased by 18% year-over-year. The company also reported a net income for the same period. These positive results could impact investor confidence and ownership trends.

Leadership Changes

Bonnie Anderson transitioned from CEO to Executive Chairman in May 2021. Marc Stapley became the new Chief Executive Officer. This transition was part of a planned succession strategy. The change in leadership aimed to ensure continued strategic guidance.

Strategic Acquisitions

The acquisition of Decipher Biosciences, Inc., was a strategic move. The acquisition was intended to boost the commercial expansion. It focused on the urologic cancer market.

Veracyte Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs